医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

不可切除肺鳞癌的预后影响因素分析

Prognostic factor analysis of patients with unresectablelung squamous cell carcinoma

摘要目的:探讨不可切除肺鳞癌的预后影响因素。方法:纳入2005年1月至2018年6月就诊于中国医科大学附属第一医院、不能手术切除的局部晚期或复发转移(Ⅲa~Ⅳ期)肺鳞癌患者350例,收集患者的临床病理资料和生存资料,采用Kaplan-Meier法进行生存分析,采用单因素分析和多因素Cox回归分析明确预后独立影响因素。结果:350例肺鳞癌患者的中位生存时间为16.7个月。单因素分析结果显示,临床分期、美国东部肿瘤协作组(ECOG)评分、化疗线数、化疗疗效、是否放疗、化疗前C反应蛋白(CRP)、乳酸脱氢酶(LDH)、癌胚抗原(CEA)、癌抗原125(CA125)、是否骨转移、是否脑转移和是否肝转移与晚期肺鳞癌患者的预后有关(均 P<0.05)。Cox多因素分析显示,ECOG评分( HR=1.855,95% CI为1.063~3.239, P=0.030)、既往是否行肺切除术( HR=0.476,95% CI为0.302~0.751, P=0.001)、一线化疗疗效(疾病稳定: HR=0.293,95% CI为0.159~0.540, P<0.001;完全缓解+部分缓解: HR=0.223,95% CI为0.120~0.413, P<0.001)、化疗前CRP( HR=1.715,95% CI为1.080~2.723, P=0.042)、LDH( HR=1.116,95% CI为0.780~1.596, P=0.002)、CEA( HR=1.855,95% CI为1.361~2.528, P<0.001)、是否肝转移( HR=2.453, 95% CI为1.461~4.120, P=0.001)是不可切除肺鳞癌患者的独立预后影响影响因素。 结论:ECOG评分、既往是否行肺切除术、一线化疗疗效、化疗前CRP、LDH及CEA水平、是否发生肝转移是晚期不可手术肺鳞癌患者的独立预后影响因素。

更多

abstractsObjective:To investigate the prognostic factors associated with unresectable (stage Ⅲa-Ⅳ, according to the 7th edition of the AJCC cancer staging manual) lung squamous cell carcinoma.Methods:We retrospectively analyzed 350 patients with inoperable locally advanced, recurrent or metastatic lung squamous cell carcinoma who were admitted to the First Affiliated Hospital of Chinese Medical University from January 2005 to June 2018. The clinical pathological data, treatment and survival follow-up information of the patients were collected. Kaplan-Meier survival was used to compare the overall survival rate of different risk groups. Univariate analysis and multivariate Cox regression analysis were used to determine the independent prognostic factors.Results:A total of 350 patients were enrolled. The median overall survival (OS) of these patients was 16.7 months. Univariate analysis showed the stage, Eastern Cooperative Oncology Group(ECOG), first-line chemotherapy evaluation (RECIST version 1.1), radiation therapy, number of systemic chemotherapy lines, carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), C reactive protein (CRP), lactate dehydrogenase (LDH), whether liver, brain, boneor metastasis were associated with the OS of patients with advanced lung squamous cell carcinoma (all P<0.05). Multivariate analysis showed that ECOG score ( HR=1.855, 95% CI: 1.063-3.239, P=0.030), whether underwent lung resection ( HR=0.476, 95% CI: 0.302-0.751, P=0.001), first-line chemotherapy evaluation [stable disease (SD): HR=0.293, 95% CI: 0.159-0.540, P<0.001; complete response (CR)+ partial response (PR): HR=0.223, 95% CI: 0.120-0.413, P<0.001], CRP ( HR=1.715, 95% CI: 1.080-2.723, P=0.042), LDH ( HR=1.116, 95% CI: 0.780-1.596, P=0.002) and CEA ( HR=1.855, 95% CI: 1.361-2.528, P<0.001) before chemotherapy, liver metastasis ( HR=2.453, 95% CI: 1.461-4.120, P=0.001) are independent prognostic factors for patients with unresectable lung squamous cell carcinoma. Conclusion:The ECOG score, surgical treatment history, first-line chemotherapy, LDH, CEA and CRP before chemotherapy, liver metastasis are independent prognostic factors for patients with advanced lung squamous cell carcinoma.

More
广告
栏目名称
DOI 10.3760/cma.j.cn112152-20191126-00763
发布时间 2026-03-31(万方平台首次上网日期,不代表论文的发表时间)
  • 浏览383
  • 下载104
中华肿瘤杂志

中华肿瘤杂志

2021年43卷5期

569-573页

MEDLINEISTICPKUCSCDCA

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷